Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced it will present two presentations at the upcoming ObesityWeek® 2026 Annual Meeting, taking place November 14-17, 2026, in Washington, D.C.

The first late-breaking oral presentation will feature topline results from the Phase 3 LUCIDITY clinical trial of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist, in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery. This follows the Company’s announcement of positive topline results from LUCIDITY in August 2026. PBH is a chronic metabolic condition driven by an exaggerated GLP-1 response, primarily after food intake, leading to persistent, recurrent, and often debilitating rapid drops in blood glucose, known as hypoglycemia. Avexitide is a competitive GLP-1 receptor antagonist designed to inhibit the exaggerated GLP-1-driven insulin response, reducing inappropriate insulin secretion and stabilizing blood glucose levels. PBH is associated with morbidity and impaired quality of life, and there is no FDA-approved therapy.

The second presentation highlights a machine learning-based approach to identifying individuals with PBH in real-world claims data. The study aims to provide insights into real world characteristics, diagnosis, and healthcare burden of people with PBH.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.